[ET Net News Agency, 6 January 2022] Credit Suisse lowered its target price for Luye
Pharma (02186) to HK$3 from HK$4.8 and downgraded its rating to "underperform" from
"neutral".
The research house said although the company could see business recovery at teens-rate
of revenue growth in 2022-23, it still lacks solid long-term growth drivers. (RC)